Bart Dunn joined Collegium Pharmaceutical in August 2019 as Executive Vice President, Strategy and Corporate Development. Prior to joining Collegium, Mr. Dunn was Senior Vice President, Corporate Development at Vivelix Pharmaceuticals, a clinical-stage biotechnology company. Previously, he served as Vice President, Strategy and Corporate Development at Patheon, a leading biopharmaceutical contract manufacturing organization, up until Patheon’s acquisition by Thermo Fisher. Prior to Patheon, he held business development, corporate development and strategic leadership roles at NuPathe Inc (acquired by Teva), Inspire Pharmaceuticals (acquired by Merck) and Pfizer. Mr. Dunn has more than 25 years of experience spanning large-cap, mid-cap specialty, and start-up companies in the pharmaceutical and over-the-counter drug industries. He has led or played an integral role in more than 40 M&A, licensing and divestiture transactions valued at more than $11 billion. Mr. Dunn holds an MBA from Saint Joseph’s University, a BBA in Accounting from Pace University, and previously practiced as a Certified Public Accountant.